Psoriasis – Pipeline Review, H1 2018

Global Markets Direct’s, ‘Psoriasis – Pipeline Review, H1 2018’, provides an overview of the Psoriasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Psoriasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Psoriasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Psoriasis

– The report reviews pipeline therapeutics for Psoriasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Psoriasis therapeutics and enlists all their major and minor projects

– The report assesses Psoriasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Psoriasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Psoriasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Psoriasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

AbbVie Inc

Abeome Corp

AbGenomics International Inc

Aclaris Therapeutics Inc

Adello Biologics LLC

Affibody AB

Alfacyte Ltd

Allergan Plc

Almirall SA

Alteogen Inc

Amgen Inc

AnaptysBio Inc

ApoPharma Inc

Arbor Pharmaceuticals LLC

Arrien Pharmaceuticals LLC

AstraZeneca Plc

Athenex Inc

Atlantic Bio Sci LLC

Aurigene Discovery Technologies Ltd

Baliopharm AG

Bayer AG

Beta Pharma Inc

BioApex sro

Biocad

Biocon Ltd

BioLingus AG

Bionomics Ltd

Bionovis SA

BirchBioMed Inc

Boehringer Ingelheim GmbH

Boston Pharmaceuticals Inc

Brickell Biotech Inc

Bristol-Myers Squibb Co

C4X Discovery Holdings PLC

CalciMedica Inc

Can-Fite BioPharma Ltd

Celgene Corp

Celon Pharma SA

ChemoCentryx Inc

ChironWells GmbH

Coherus BioSciences Inc

Compugen Ltd

Concenter BioPharma Silkim Ltd

conoGenetix biosciences GmbH

Crescita Therapeutics Inc

Dermala Inc

Dr. August Wolff GmbH & Co KG Arzneimittel

DURECT Corp

Eli Lilly and Co

ELORAC Inc

Exicure Inc

Forward Pharma AS

Fresenius SE & Co KGaA

FYB202 GmbH & Co KG

Galapagos NV

Galderma SA

Galectin Therapeutics Inc

Genentech Inc

Genfit SA

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

GlycoMar Ltd

Grunenthal GmbH

HitGen LTD

Huabo Biopharm Co Ltd

Hydra Biosciences Inc

iCo Therapeutics Inc.

Immune Pharmaceuticals Inc

Immune Response BioPharma Inc

Immungenetics AG

Immunwork Inc

Innovation Pharmaceuticals Inc

Inspyr Therapeutics Inc

Istesso Ltd

Japan Tobacco Inc

Jiangsu Hengrui Medicine Co Ltd

Johnson & Johnson

Just Biotherapeutics Inc

Kadmon Corp LLC

Kaken Pharmaceutical Co Ltd

Kang Stem Biotech Co Ltd

Kv1.3 Therapeutics

Kymab Ltd

Lead Pharma Holding BV

LEO Pharma A/S

Lupin Ltd

Lycera Corp

mAbxience SA

Maruho Co Ltd

Merck KGaA

MetrioPharm AG

Mitsubishi Tanabe Pharma Corp

Momenta Pharmaceuticals Inc

Monopar Therapeutics LLC

Mycenax Biotech Inc

Nichi-Iko Pharmaceutical Co Ltd

Nimbus Therapeutics LLC

NovaLead Pharma Pvt Ltd

Novan Inc

Novartis AG

Nuevolution AB

Numab Innovation AG

Oncobiologics Inc

Orphagen Pharmaceuticals Inc

Pfizer Inc

Pharis Biotec GmbH

Pharmedartis GmbH

Phenex Pharmaceuticals AG

Philogen SpA

PinCell srl

Pivot Pharmaceuticals Inc

Plant Advanced Technologies SA

Principia Biopharma Inc

Protalix BioTherapeutics Inc

Provectus Biopharmaceuticals Inc

Qilu Pharmaceutical Co Ltd

Realm Therapeutics Plc

RedHill Biopharma Ltd

Reliance Life Sciences Pvt Ltd

Samumed LLC

Sandoz International GmbH

Sareum Holdings Plc

SBI Biotech Co Ltd

Shanghai Henlius Biotech Co Ltd

Shulov Innovative Science Ltd

Sienna Biopharmaceuticals Inc

Sigmoid Pharma Ltd

Soligenix Inc

Spherium Biomed SL

Sterna biologicals Gmbh & Co KG

Sun Pharma Advanced Research Company Ltd

Switch Biotech LLC

Syntrix Biosystems Inc

Tasly Pharmaceutical Group Co Ltd

TheraMAB LLC

Tolero Pharmaceuticals Inc

Torrent Pharmaceuticals Ltd

UCB SA

Valeant Pharmaceuticals International Inc

Vicore Pharma AB

vTv Therapeutics Inc

Wellstat Therapeutics Corp

XBiotech Inc

Yuhan Corp

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Psoriasis Overview 9

Psoriasis Therapeutics Development 10

Psoriasis Therapeutics Assessment 41

Psoriasis Companies Involved in Therapeutics Development 57

Psoriasis Drug Profiles 120

Psoriasis Dormant Projects 644

Psoriasis Discontinued Products 662

Psoriasis Product Development Milestones 666

Appendix 680

List of Tables

List of Tables

Number of Products under Development for Psoriasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Psoriasis Pipeline by 3SBio Inc, H1 2018

Psoriasis Pipeline by AbbVie Inc, H1 2018

Psoriasis Pipeline by Abeome Corp, H1 2018

Psoriasis Pipeline by AbGenomics International Inc, H1 2018

Psoriasis Pipeline by Aclaris Therapeutics Inc, H1 2018

Psoriasis Pipeline by Adello Biologics LLC, H1 2018

Psoriasis Pipeline by Affibody AB, H1 2018

Psoriasis Pipeline by Alfacyte Ltd, H1 2018

Psoriasis Pipeline by Allergan Plc, H1 2018

Psoriasis Pipeline by Almirall SA, H1 2018

Psoriasis Pipeline by Alteogen Inc, H1 2018

Psoriasis Pipeline by Amgen Inc, H1 2018

Psoriasis Pipeline by AnaptysBio Inc, H1 2018

Psoriasis Pipeline by ApoPharma Inc, H1 2018

Psoriasis Pipeline by Arbor Pharmaceuticals LLC, H1 2018

Psoriasis Pipeline by Arrien Pharmaceuticals LLC, H1 2018

Psoriasis Pipeline by AstraZeneca Plc, H1 2018

Psoriasis Pipeline by Athenex Inc, H1 2018

Psoriasis Pipeline by Atlantic Bio Sci LLC, H1 2018

Psoriasis Pipeline by Aurigene Discovery Technologies Ltd, H1 2018

Psoriasis Pipeline by Baliopharm AG, H1 2018

Psoriasis Pipeline by Bayer AG, H1 2018

Psoriasis Pipeline by Beta Pharma Inc, H1 2018

Psoriasis Pipeline by BioApex sro, H1 2018

Psoriasis Pipeline by Biocad, H1 2018

Psoriasis Pipeline by Biocon Ltd, H1 2018

Psoriasis Pipeline by BioLingus AG, H1 2018

Psoriasis Pipeline by Bionomics Ltd, H1 2018

Psoriasis Pipeline by Bionovis SA, H1 2018

Psoriasis Pipeline by BirchBioMed Inc, H1 2018

Psoriasis Pipeline by Boehringer Ingelheim GmbH, H1 2018

Psoriasis Pipeline by Boston Pharmaceuticals Inc, H1 2018

Psoriasis Pipeline by Brickell Biotech Inc, H1 2018

Psoriasis Pipeline by Bristol-Myers Squibb Co, H1 2018

Psoriasis Pipeline by C4X Discovery Holdings PLC, H1 2018

Psoriasis Pipeline by CalciMedica Inc, H1 2018

Psoriasis Pipeline by Can-Fite BioPharma Ltd, H1 2018

Psoriasis Pipeline by Celgene Corp, H1 2018

Psoriasis Pipeline by Celon Pharma SA, H1 2018

Psoriasis Pipeline by ChemoCentryx Inc, H1 2018

Psoriasis Pipeline by ChironWells GmbH, H1 2018

Psoriasis Pipeline by Coherus BioSciences Inc, H1 2018

Psoriasis Pipeline by Compugen Ltd, H1 2018

Psoriasis Pipeline by Concenter BioPharma Silkim Ltd, H1 2018

Psoriasis Pipeline by conoGenetix biosciences GmbH, H1 2018

Psoriasis Pipeline by Crescita Therapeutics Inc, H1 2018

Psoriasis Pipeline by Dermala Inc, H1 2018

Psoriasis Pipeline by Dr. August Wolff GmbH & Co KG Arzneimittel, H1 2018

Psoriasis Pipeline by DURECT Corp, H1 2018

Psoriasis Pipeline by Eli Lilly and Co, H1 2018

Psoriasis Pipeline by ELORAC Inc, H1 2018

Psoriasis Pipeline by Exicure Inc, H1 2018

Psoriasis Pipeline by Forward Pharma AS, H1 2018

Psoriasis Pipeline by Fresenius SE & Co KGaA, H1 2018

Psoriasis Pipeline by FYB202 GmbH & Co KG, H1 2018

Psoriasis Pipeline by Galapagos NV, H1 2018

Psoriasis Pipeline by Galderma SA, H1 2018

Psoriasis Pipeline by Galectin Therapeutics Inc, H1 2018

Psoriasis Pipeline by Genentech Inc, H1 2018

Psoriasis Pipeline by Genfit SA, H1 2018

Psoriasis Pipeline by Genor BioPharma Co Ltd, H1 2018

Psoriasis Pipeline by GlaxoSmithKline Plc, H1 2018

Psoriasis Pipeline by GlycoMar Ltd, H1 2018

Psoriasis Pipeline by Grunenthal GmbH, H1 2018

Psoriasis Pipeline by HitGen LTD, H1 2018

List of Figures

List of Figures

Number of Products under Development for Psoriasis, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1 2018

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports